Detalhe da pesquisa
1.
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
Ann Oncol
; 30(6): 970-976, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31050707